3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neuroblastoma
19
Lung Neoplasms
3
Uterine Cervical Neoplasms
2
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Ganglioneuroblastoma
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Recurrence
1
Penile Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Neoplasm, Residual
1
Mycosis Fungoides
1
Multiple Myeloma
1
Lymphoma, T-Cell
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Myeloid, Acute
1
Leukemia, Monocytic, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Erythroblastic, Acute
1
Leukemia
1
Keratosis, Actinic
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Glioma
1
Interventions
Amifostine
10
Cisplatin
8
Radiotherapy
7
Etoposide
6
Cyclophosphamide
4
Carboplatin
4
Paclitaxel
3
pegfilgrastim
2
camrelizumab
2
apatinib
2
Mitoxantrone
2
Filgrastim
2
Drug Therapy
2
Cytarabine
2
sodium thiosulfate
1
sargramostim
1
pazopanib
1
icotinib
1
glucarpidase
1
etoposide phosphate
1
denileukin diftitox
1
Vitamin E
1
Triptorelin Pamoate
1
Tocopherols
1
Thiotepa
1
Tegafur
1
Taxes
1
Surgical Procedures, Operative
1
Silymarin
1
Rituximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Drug-Related Side Effects and Adverse Reactions
×
Isotretinoin
×
Clear all
NCT00002586
2020-05-15
13-Cis
University of Colorado, Denver
Phase 2
Completed
96 enrolled